Drug Profile


Alternative Names: BAP 909; Erechrome

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute of Materia Medica
  • Developer Jiangsu Hengrui Medicine Co.
  • Class Anti-inflammatories; Pyrroles; Small molecules; Sulfides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Osteoarthritis
  • No development reported Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Inflammation in China (PO)
  • 22 Dec 2015 Jiangsu HengRui Medicine Co. initiates a phase I drug-drug interaction trial in Healthy volunteers in China (PO) (ChiCTR-OIB-15007606)
  • 01 Jan 2015 Jiangsu HengRui Medicine Co. initiates enrolment in a phase I trial for Osteoarthritis in China (NCT02456688)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top